A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 5, 2012, Pages 673-681

  Salazar, R ^a   Jones, R J ^b   Oaknin, A ^a   Crawford, D ^b   Cuadra, C ^a   Hopkins, C ^b   Gil, M ^a   Coronado, C ^c   Soto Matos, A ^c   Cullell Young, M ^c   Dios, J L Iglesias ^c   Evans, T R J ^b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c PHARMAMAR S A   (Spain)

Author keywords

Anti proliferative; Depsipeptide; Kahalalide F; Pharmacokinetics; Phase I study

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATINE KINASE; CREATININE; ELISIDEPSIN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BODY SURFACE; BREAST ADENOCARCINOMA; CANCER PAIN; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CARCINOMA; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DISTRIBUTION VOLUME; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; ENDOMETRIUM CARCINOMA; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER CARCINOMA; HEAD AND NECK CARCINOMA; HEART DISEASE; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MERKEL CELL TUMOR; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PRURITUS; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; URINARY FREQUENCY; UTERINE CERVIX CARCINOMA; UTERUS SARCOMA; VENTRICULAR HYPOKINESIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TRANSAMINASES; TREATMENT OUTCOME;

EID: 84871197062     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1951-6     Document Type: Article

References (28)

1. Hamann MT, Otto CS, Scheuer PJ, Dunbar DC (1996) Kahalalides: bioactive peptides from a marine mollusk Elysia rufescens and its algal diet bryopsis sp. (1). J Org Chem 61:6594-6600
2. Sparidans RW, Stokvis E, Jimeno JM, Lopez-Lazaro L, Schellens JH, Beijnen JH (2001) Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F. Anticancer Drugs 12:575-582
3. Faircloth G, Cuevas C (2006) Kahalalide F and ES285: potent anticancer agents from marine molluscs. Prog Mol Subcell Biol 43:363-379
4. Provencio M, Sanchez A, Gasent J, Gomez P, Rosell R (2009) Cancer treatments: can we find treasures at the bottom of the seǎ Clin Lung Cancer 10:295-300
5. Ling YH, Aracil M, Jimeno J, Perez-Soler R, Zou Y (2009) Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer 45:1855-1864
6. Elices M, Lepage DJ, Grant W, Alvarez E, Guillen MJ, Cuevas C, Aviles P, Faircloth G (2006) Activity of PM02734 against human breast and prostate tumors. Proc Am Assoc Cancer Res 47 (Abst. 4712)
7. Herrero AB, Astudillo AM, Balboa MA, Cuevas C, Balsinde J, Moreno S (2008) Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734. Cancer Res 68:9779-9787
8. Molina-Guijarro JM, Moneo V, Marti'nez-Leal JF, Cuevas C, Garci'a-Ferna'ndez LF, Galmarini CM (2009) PM02734, a new marine-derived antitumoral compound, has rapid effects on membrane integrity and permeability in tumor cells. Paper presented at the proceedings of the 100th annual meeting of the American association for cancer research
9. Coronado C, Galmarini CM, Alfaro V, Yovine A (2010) Elisidepsin. Drugs Fut 35:287-296
10. Sasak H, Yin J, Elices M, LePage D, Cuevas Marchante C, Aviles P, Faircloth G (2006) PM02734 cytotoxicity in vitro and pharmacokinetics. Proc Am Assoc Cancer Res 47 (Abst. 1911)
11. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
13. Yin J, Aviles P, Lee W, Ly C, Guillen MJ, Munt S, Cuevas C, Faircloth G (2006) Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma. Rapid Commun Mass Spectrom 20:2735-2740
14. Bruce JY, Geary D, De las Heras B, Soto A, Garcia Paramio P, Yovine A, Schilsky RL, Undevia SD, Ratain MJ (2008) Phase I study of PM02734: association of dose-limiting hepatotoxicity with plasma concentrations. J Clin Oncol 26 (Abstract 2513)
15. Hama H, Young DA, Radding JA, Ma D, Tang J, Stock SD, Takemoto JY (2000) Requirement of sphingolipid alphahydroxylation for fungicidal action of syringomycin E. FEBS Lett 478:26-28
16. Nyholm PG, Pascher I, Sundell S (1990) The effect of hydrogen bonds on the conformation of glycosphingolipids. Methylated and unmethylated cerebroside studied by X-ray single crystal analysis and model calculations. Chem Phys Lipids 52:1-10
17. Brown DA, London E (1998) Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 14:111-136
18. Molina-Guijarro JM, Macias A, Garcia C, Munoz E, Garcia-Fernandez LF, David M, Nunez L, Martinez-Leal JF, Moneo V, Cuevas C, Lillo MP, Villalobos Jorge C, Valenzuela C, Galmarini CM (2011) Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells. PLoS ONE 6:e19042
19. Suarez Y, Gonzalez L, Cuadrado A, Berciano M, Lafarga M, Munoz A (2003) Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2:863-872
20. Sewell JM, Mayer I, Langdon SP, Smyth JF, Jodrell DI, Guichard SM (2005) The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines. Eur J Cancer 41:1637-1644
21. Garcia-Rocha M, Bonay P, Avila J (1996) The antitumoral compound Kahalalide F acts on cell lysosomes. Cancer Lett 99:43-50
22. Cruz LJ, Luque-Ortega JR, Rivas L, Albericio F (2009) Kahalalide F, an antitumor depsipeptide in clinical trials, and its analogues as effective antileishmanial agents. Mol Pharm 6:813-824
23. Reuben A (2004) Hy's law. Hepatology 39:574-578
24. Temple R (2006) Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 15:241-243
25. Coronado C, Kahatt C, Szyldergemajn S, Iglesias JL, Florez A, Yovine A (2010) Transient isolated transaminase increases do not correlate with permanent clinical liver damage: phase I experience with Elisidepsin. Ann Oncol 21:180-181
26. Rademaker-Lakhai JM, Horenblas S, Meinhardt W, Stokvis E, de Reijke TM, Jimeno JM, Lopez-Lazaro L, Lopez Martin JA, Beijnen JH, Schellens JH (2005) Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin Cancer Res 11:1854-1862
27. Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, Garcia M, Salazar R, Lopez A, Blanco M, Nieto A, Jimeno J, Izquierdo MA, Trigo JM (2008) Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Clin Cancer Res 14:1116-1123
28. Martin-Algarra S, Espinosa E, Rubio J, Lopez Lopez JJ, Manzano JL, Carrion LA, Plazaola A, Tanovic A, Paz-Ares L (2009) Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. Eur J Cancer 45:732-735